Anondita Medicare Limited · NSE:ANONDITA
Anondita Medicare — India Inc. Unplugged by PhillipCapital – Private Client Group 2026
44 slides from Anondita Medicare's conference presentation, Jun 22, 2026
Slide 1: Submission of Investor Presentation to NSE
June 22, 2026 To, The Manager, Listing Compliance Department National Stock Exchange of India Limited Exchange Plaza, Bandra Kurla Complex, Bandra (East), Mumbai-400051 Subject: Submission of Investor Presentation for the Investor Conference, “India Inc. Unplugged by PhillipCapital – Private Client
Slide 2: Investor Presentation
(Formerly known as Anondita Healthcare) Investor Presentation 10
Slide 3: Safe Harbour Statement
Safe Harbour Statement This presentation and its accompanying materials (collectively, the "Presentation") have been prepared by Anondita Medicare Limited ("Anondita," "the Company," or "we") for informational and discussion purposes only. This Presentation does not constitute an offer to sell or so
Slide 4: About Anondita Medicare Limited
About Anondita Medicare Limited Anondita Medicare Limited, is an Indian manufacturer of male and female condoms, operating under its flagship brand “COBRA.” The company runs its own manufacturing facility and follows a quality-driven, compliant production model. The company is led by Mr. Anupam Ghos
Slide 5: Management Overview
Management Overview Mr. Anupam Ghosh Mr. Reshant Ghosh Mr. Lakhinder Singh IRS Retired Managing Director & Promoter Whole -Time Director & Promoter Director Role & Experience Role & Experience Role & Experience • Over 25 years of experience in the healthcare • Founder and CEO of Anondita Healthcare
Slide 6: Mission & Vision
Mission & Vision MISSION ROADMAP VISION 2026 Anondita Medicare Ltd. aspires to be a leading Addition of manufacturing facilities for female latex condoms. force in the fight against HIV/AIDS and the 2027 prevention of unintended pregnancies by Commencement of female latex condom manufacturing. deliv
Slide 7: Key Facts & Figures
Key Facts & Figures 30+ 15 FY26 H2 FY26 Years of Experience Manufacturing lines Revenue – 13,741.57 Revenue – 8,331.87 EBITDA – 5,150.85 EBITDA – 3,189.92 Net Profit – 3,429.65 Net Profit – 2,127.86 280+ Team Size Quality Assurance • Stringent quality control processes • Each and Every Condom is Ele
Slide 8: Key Events And Milestones
Key Events And Milestones 1999 2019 2011-2015 • Got mentioned In various articles in • The erstwhile proprietorship “M/s newspapers, newsletters, etc., and Health Care Products” was started awards as a leading manufacturer of by our current promoter, • Got our factory approved by KFW condoms and sur
Slide 9: Establishment of the Brand “Cobra Condoms”
Establishment of the Brand “Cobra Condoms” After years of supplying our products to top pharmaceutical companies like German Remedies Pharmaceuticals Pvt. Ltd., Zydus Cadila, Koye Pharmaceuticals Pvt. Ltd, we have now entered the market with our subsidiary’s brand - Cobra Condoms. Key Highlights Eac
Slide 10: Types of Condoms
Types of Condoms Extra Large Ultra-Thin Dotted Multi-textured 01 Condoms 02 Condoms 03 Condoms 04 Condoms Extra Strong Plain Ribbed Female 05 Condoms 06 Condoms 07 Condoms 08 Condoms Investor Presentation 9
Slide 11: Manufacturing Facility
Manufacturing Facility Enabling operational scale-up and future growth Condoms Production Capacity Installed Capacity Utilization Capacity Utilization Capacity (%) Noida, Uttar Pradesh Location 10,000.00 90.00% ~9,290 Sq. Mt. 8,690.00* Total built-up area 9,000.00 80.67% 80.00% 8,000.00 70.00% 5,620
Slide 12: Scaling Manufacturing Capabilities – Noida Facility
Scaling Manufacturing Capabilities – Noida Facility Project Investment & Funding For On Going Expansion Change photo Estimated project cost: ~₹75 crore + Taxes Funding mix: • Internal accruals • Debt • Fund raising by Preferential issue etc Focus on financial discipline and operational leverage R&D
Slide 13: Cobra Product Portfolio (Flavors & Types)
Cobra Product Portfolio (Flavors & Types) 01 Strawberry 02 Mint 03 Chocolate 04 Butterscotch 05 Coffee 06 Bubblegum Cobra® Premium Classic Fit Cobra® Premium Super Dotted Cobra® Premium Multi Texture Dotted & Ribbed Cobra® Premium Classic Fit • Lubricated Latex Condoms • Lubricated Latex Condoms • R
Slide 14: Premium Condom Manufacturing Excellence
Premium Condom Manufacturing Excellence Integrated Male & Female Condom Capability Creates Strong Global Market Opportunity FEMALE CONDOM MARKET OPPORTUNITY MANUFACTURING DIFFERENTIATION • Anondita Medicare Limited manufactures both Male & Female Latex Condoms. • Dedicated manufacturing capability f
Slide 15: Pan-India Distribution & Market Presence
Pan-India Distribution & Market Presence Our Distribution Pyramid State Wise Market Presence & Strong Network, Wider Reach Distribution Network Rajasthan Maharashtra Super Stockist: 2 Super Stockist: 3 Distributor: 14 Distributor: 36 Retailers: 611 Retailers: 1721 Wider Coverage 26 Expanding Our Pre
Slide 16: Management Priorities & Targets
Management Priorities & Targets Revenue & Margin Targets Product Innovation Market Expansion 60–70% revenue growth by FY27 Expanding premium condoms, Targeting 25% export with EBITDA margins of approx. latex variants & diagnostic contribution by FY27 through 30% healthcare products. strategic global
Slide 17: Building Trust, Delivering Excellence
Building Trust, Delivering Excellence • Ipo Launch Successfully Key Achievements & Growth Launched IPO On NSE Drivers • South Africa Audit • NSE Listed Company Successfully Completed South Africa Audit. • UN of Brazil Recognition • International Expansion Strengthening Exports Across Brazil, South A
Slide 18: Future Product Expansion & Innovation Strategy
Future Product Expansion & Innovation Strategy Anondita Medicare Limited is committed to strengthening its presence in the healthcare and in sexual wellness products category through continuous innovation, product diversification, and expansion into new healthcare categories. Following the successfu
Slide 19: MDSAP Certification Received Under ISO 13485:2016
MDSAP Certification Received Under ISO 13485:2016 Scope of Certification Covers male and female condoms Enables marketing across five regulated international jurisdictions: Australia Brazil Canada Japan United States of America Strategic Importance Provides access to highly regulated medical device
Slide 20: Receives SABS Certification for Male Condoms
Receives SABS Certification for Male Condoms • Received SABS certification for natural rubber latex male condoms • Certification as per SANS 4074:2017 standards • Applies to select COBRA brand variants Strategic Significance • Enables access to regulated export markets • South Africa • Africa-focuse
Slide 21: Certifications
Certifications Investor Presentation 20
Slide 22: Establishment of the Brand “Cobra Condoms”
Establishment of the Brand “Cobra Condoms” 1 Global Expansion Scale exports beyond Africa into high- potential international markets. 2 UN qualification In advanced stages, enabling access to global markets, with exports targeted to begin by end- FY26 or early next Q1FY26. 3 4 1 2 3 4 Automation & E
Slide 23: SWOT Analysis
SWOT Analysis Strengths Weaknesses S W Established condom manufacturer in India with own Dependence on latex raw material supply, exposing the brand and manufacturing facility. business to procurement and price volatility. Strong demand driven by rising STD awareness and Advantage as one of the few
Slide 24: Global Condom Market Outlook
Global Condom Market Outlook Global Condom Market In USD Billion Global Procurement & Donor Market (Volumes) 17.57 8.10% CAGR 11.9 UNFPA: Total global institutional ~680+ million male condoms + distribution: ~6 million female condoms ~1.5–2.0 billion condoms annually across Africa, Asia & per year,
Slide 25: Indian Condom Market Outlook
Indian Condom Market Outlook India Condom Market Indian Condom Market Segmentation USD Million 773.82 35% 30% 25% 7.45 CAGR 20% 406.31 15% 30% 25% 10% 22% 23% 5% 0% East India North India West & Central India South India FY24 FY33 Based on Product Type: • Male condoms dominate the Indian market with
Slide 26: Future Market Potential & Global Growth
Future Market Potential & Global Growth 1. Domestic Government Procurement 4. Building the COBRA Brand Strong presence Diversified in Client Global institutional Base healthcare procurement Strengthening COBRA as a premium Comprehensive domestic Service and In-House programs including NACO, Nirodh &
Slide 27: India Condom Market Share
India Condom Market Share MARKET SIZE (INDIA) FY26 (EST.) : INR 2,600 – 2,800 CRORE MANFORCE (Mankind Pharma) Others Include 27% (Key Players) 30% HLL Lifecare Limited (Moods / Nirodh) Durex (Reckitt) • Anondita Medicare Ltd • Pakka Limited SKORE CONDOMS (TTK Healthcare) 3% • Parag Rubber Industries
Slide 28: Global Female Condom Market
Global Female Condom Market Global Female Condom Market Size Estimated Global Market Share 2–5 Billion Pieces Annually (Potential Company Market Share Demand) Veru Inc. (FC2) 55%–70% 700 Million To 1.5 Billion Cupid Limited 20%–30% Pieces Annually (Commercial/Public Procurement HLL Lifecare Limited
Slide 29: Anondita Medicare: Leading Condom Manufacturer
Anondita Medicare: Leading Condom Manufacturer Total Production Capacity Total Projected Revenue Our Commitment ❖ High manufacturing capacity 1,119 241 Million Million Male Condoms Female Condoms ❖ Global quality standards (250 WIP) (WIP) ❖ Focus on safety, reliability and TOTAL 1000+ accessibility
Slide 30: Demand Drivers
Demand Drivers Large youth population & Urbanisation, rising disposable demographic dividend incomes and premiumisation India has the world’s largest youth cohort (15–29 years ~370–420M) and more consumers in urban / tier-2/3 cities willing to pay for a low median age (~29). A large sexually active
Slide 31: Financial Snapshot (Consolidated)
Financial Snapshot (Consolidated) Figures In ₹ Lakhs, Margin In %, EPS in ₹ Revenue from Operations EBITDA EBITDA Margin PAT PAT Margin EPS 26.00% 2,500.00 39.00% 3,500.00 8,331.87 3,189.92 2,127.8 25.50% 6 25.54% 38.29% 3,000.00 11.76 38.00% 2,000.00 25.00% 9.31 2,500.00 24.50% 37.00% 1,500.00 2,00
Slide 32: Income Statement (Consolidated)
Income Statement (Consolidated) (Subsidiary, Anondita Healthcare and Rubber Products India Ltd., w.e.f. 01/04/2024) Figures In ₹ Lakhs, Margin In %, EPS in ₹ Particulars H2 FY26 H2 FY25 YOY Revenue from operations 8,331.87 4,558.57 83% Other Income 43.46 3.61 Total Revenue 8,375.33 4,562.18 84% Cost
Slide 33: Financial Snapshot (Standalone)
Financial Snapshot (Standalone) Figures In ₹ Lakhs, Margin In %, EPS in ₹ Revenue from Operations EBITDA EBITDA Margin PAT PAT Margin EPS 24.20% 1,800.00 37.00% 2,500.00 2,352.69 1,535.4 6,404.56 4 23.97% 24.00% 1,600.00 36.80% 36.73% 8.49 23.80% 36.60% 2,000.00 1,400.00 23.60% 36.40% 1,200.00 23.40
Slide 34: Income Statement (Standalone)
Income Statement (Standalone) (Subsidiary, Anondita Healthcare and Rubber Products India Ltd., w.e.f. 01/04/2024) Figures In ₹ Lakhs, Margin In %, EPS in ₹ Particulars H2 FY26 H2 FY25 YOY Revenue from operations 6,404.56 3,554.47 80% Other Income 100.35 7.73 Total Revenue 6,504.91 3,562.20 83% Cost
Slide 35: Income Statement (Consolidated)
Income Statement (Consolidated) Figures In ₹ Lakhs, Margin In %, EPS in ₹ Anondita medicare Ltd Anondita Helthcare (Prop) Particulars FY26 FY25 FY24 Revenue from operations 13,741.57 7,699.07 4,643.21 Other Income 84.24 13.88 12.33 Total Revenue 13,825.81 7712.95 4,655.53 Cost of materials Consumed
Slide 36: Balance sheet (Consolidated)
Balance sheet (Consolidated) (Subsidiary, Anondita Healthcare and Rubber Products India Ltd., w.e.f. 01/04/2024) Figures In ₹ Lakhs, Margin In %, EPS in ₹ Anondita Medicare Limited Anondita Healthcare (Prop) Equities and Liabilities FY26 FY25 FY24 Shareholder's Funds Share Capital 1808.66 1,329.36 2
Slide 37: Balance sheet (Consolidated)
Balance sheet (Consolidated) (Subsidiary, Anondita Healthcare and Rubber Products India Ltd., w.e.f. 01/04/2024) Figures In ₹ Lakhs, Margin In %, EPS in ₹ Anondita Medicare Ltd Anondita Healthcare Ltd Assets FY26 FY25 FY24 Non-current Assets Fixed Assets 3,909.76 1237.04 1,014.13 Goodwill 19.18 19.1
Slide 38: Cashflow Statement (Consolidated)
Cashflow Statement (Consolidated) (Subsidiary, Anondita Healthcare and Rubber Products India Ltd., w.e.f. 01/04/2024) Figures In ₹ Lakhs, Margin In %, EPS in ₹ Anondita Medicare Ltd Anondita Healthcare Ltd Cash Flow Statement FY26 FY25 FY24 Net Cash Flow from operating activities 1,063.81 -740 1054.
Slide 39: Income Statement (Standalone)
Income Statement (Standalone) (Subsidiary, Anondita Healthcare and Rubber Products India Ltd., w.e.f. 01/04/2024) Figures In ₹ Lakhs, Margin In %, EPS in ₹ Income Statement (in ₹ Lakhs) FY26 FY25 Revenue from operations 11,169.62 6,051.52 Other Income 175.91 36.38 Total Revenue 11,345.53 6,087.90 Co
Slide 40: Balance sheet (Standalone)
Balance sheet (Standalone) (Subsidiary, Anondita Healthcare and Rubber Products India Ltd., w.e.f. 01/04/2024) Figures In ₹ Lakhs, Margin In %, EPS in ₹ Equities and Liabilities FY26 FY25 Assets FY26 FY25 Shareholder's Funds Non-current Assets Share Capital 1,808.66 1,329.36 Fixed Assets 3,907.98 1,
Slide 41: Cashflow Statement (Standalone)
Cashflow Statement (Standalone) (Subsidiary, Anondita Healthcare and Rubber Products India Ltd., w.e.f. 01/04/2024) Figures In ₹ Lakhs, Margin In %, EPS in ₹ Anondita Medicare Ltd Particulars FY26 FY25 Net Cash Flow from operating activities 378.85 1,986.42 Net Cash Flow from Investing activities -6
Slide 42: Strategy Going Forward
Strategy Going Forward Expanding Global Reach UN Qualification and • Anondita Medicare Ltd. has obtained the SABS licence from the South African Bureau of Standards, confirming Export Launch compliance with national and international quality, • The Company is applying for UNFPA Pre- safety, and perf
Slide 43: Goal for FY26
Goal for FY26 Increase production Develop innovative Implement sustainable Launch community capacity contraceptives practices education programs Export to Brazil and South To increase our market share American countries in condom industry Expand distribution Develop robust quality Advocate for polic
Slide 44: THANK YOU
THANK YOU Anondita Medicare Limited Flat No.704 Narmada Block, N6, Sec-D, Pkt-6 Vasant Kunj, New Delhi, India110070. Telephone No.: +91 7678182056 Website: www.anonditamedicare.com Email id: info@anonditamedicare.com Corporate Communication Advisors Phone: +91 82085 63201 Email: letsconnect@orim.in
Anondita Medicare — India Inc. Unplugged by PhillipCapital – Private Client Group 2026 on 6ix